Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor (BEB55) or GS-nitroxide

Hyun Kim, Mark E. Bernard, Michael W. Epperly, Hongmei Shen, Andrew Amoscato, Tracy M. Dixon, Alexander S. Doemling, Song Li, Xiang Gao, Peter Wipf, Hong Wang, Xichen Zhang, Valerian E. Kagan, Joel S. Greenberger

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

Background/Aim: Esophagitis is a significant toxicity of radiation therapy for lung cancer. In this study, reduction of irradiation esophagitis in mice, by orally administered p53/Mdm2/Mdm4 inhibitor, BEB55, or the GS-nitroxide, JP4-039, was evaluated. Materials and Methods: BEB55 or JP4-039 in F15 (liposomal) formulation was administered intraesophageally to C57BL/6 mice prior to thoracic irradiation of 29 Gy x 1 or 11.5 Gy x 4 thoracic irradiation. Progenitor cells were sorted from excised esophagus, and nitroxide was quantified, by electron paramagnetic resonance (EPR). Mice with Lewis lung carcinoma (3LL) orthotopic lung tumors were treated with BEB55 or JP4-039 prior to 20 Gy to determine if the drugs would protect the tumor cells from radiation. Results: Intraesophageal BEB55 and JP4-039 compared to formulation alone increased survival after single fraction (p=0.0209 and 0.0384, respectively) and four fraction thoracic irradiation (p=0.0241 and 0.0388, respectively). JP4-039 was detected in esophagus, liver, bone marrow, and orthotopic Lewis lung carcinoma (3LL) tumor. There was no significant radiation protection of lung tumors by BEB55 or JP4-039 compared to formulation only as assessed by survival (p=0.3021 and 0.3693, respectively). Thus, BEB55 and JP4-039 safely ameliorate radiation esophagitis in mice.

Original languageEnglish
Pages (from-to)841-848
Number of pages8
JournalIn Vivo
Volume25
Issue number6
StatePublished - Nov 1 2011
Externally publishedYes

Keywords

  • BEB55
  • Esophagitis
  • JP4-039
  • Mdm2
  • Mdm4
  • P53
  • Radiation protection

Fingerprint Dive into the research topics of 'Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor (BEB55) or GS-nitroxide'. Together they form a unique fingerprint.

  • Cite this

    Kim, H., Bernard, M. E., Epperly, M. W., Shen, H., Amoscato, A., Dixon, T. M., Doemling, A. S., Li, S., Gao, X., Wipf, P., Wang, H., Zhang, X., Kagan, V. E., & Greenberger, J. S. (2011). Amelioration of radiation esophagitis by orally administered p53/Mdm2/Mdm4 inhibitor (BEB55) or GS-nitroxide. In Vivo, 25(6), 841-848.